摘要
目的探讨达格列净对门冬胰岛素30治疗血糖控制不达标的超重或肥胖2型糖尿病(T2DM)患者的疗效和安全性。方法选取2018年10月至2019年7月十堰市人民医院内分泌科就诊的应用门冬胰岛素30治疗血糖控制不达标的48例超重或肥胖型T2DM患者作为研究对象,采用随机数字表法分为观察组和对照组,每组24例。对照组采用门冬胰岛素30联合口服传统降糖药物,观察组在对照组降糖方案基础上联用达格列净10 mg治疗,连续治疗12周后比较治疗前后两组综合指标控制情况。结果治疗12周后,两组空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbA1c)、体质量指数(BMI)、血压、尿酸、胰岛素剂量等指标比较,差异有统计学意义(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论使用门冬胰岛素30控制不达标的超重或肥胖T2DM患者联合使用达格列净,可显著降低患者血糖、BMI,减少胰岛素剂量,同时有一定的降压、降尿酸作用,不良反应发生率相对传统降糖药物较低,安全性较高。
Objective To investigate the effectiveness and safety of dapagliflozin for patients with overweight or obesity type 2 diabetes mellitus(T2DM)who have poor glycemic control.Methods Fortyeight cases of overweight or obesity T2DM patients who were accepted the treatment of biphasic insulin aspart 30 with substandard blood glucose control were enrolled from the Department of Endocrinology,Shiyan People’s Hospital from September 2018 to June 2019.According to the random number table method,all patients were divided into the experimental group and the control group.The control group was treated with insulin aspart 30 combined with oral traditional hypoglycemic drugs,and the observation group was treated with dapagliflozin 10 mg on the basis of the hypoglycemic regimen of the control group.After 12 weeks of continuous treatment,the comprehensive index control of the two groups before and after treatment was compared.Results After 12 weeks of treatment,there were statistically significant differences in HbA1c,FPG,2hPG,BMI,blood pressure,uric acid and insulin dose between the two groups(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion For overweight or obesity T2DM patients who fail to reach the standard controlled by biphasic insulin aspart 30,combined use of dapagliflozin can significantly reduce the patient’s blood glucose,BMI,and insulin dose.At the same time,it has a certain effect of lowering blood pressure and uric acid with relatively lower incidence of adverse reactions and higher safety.
作者
聂燕
丁洪成
朱名洁
李艳丽
汪茜
刘诗苑
NIE Yan;DING Hong-cheng;ZHU Ming-jie;LI Yan-li;WANG Qian;LIU Shi-yuan(Postgraduate Training Base of Jinzhou Medical University,Department of Endocrinology,Renmin Hospital,Hubei University of Medicine,Shiyan,Hubei 442000,China;不详)
出处
《慢性病学杂志》
2021年第2期182-186,共5页
Chronic Pathematology Journal
基金
十堰市科学技术局科研项目(18Y68)
关键词
达格列净
2型糖尿病
超重
肥胖
疗效
安全性
Dapagliflozin
Type 2 diabetes mellitus
Overweight
Obesity
Effectiveness
Safety
